Terms: = Prostate cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Prognosis
50 results:
1. Review on the Role of BRCA Mutations in Genomic Screening and Risk Stratification of prostate cancer.
Kalampokis N; Zabaftis C; Spinos T; Karavitakis M; Leotsakos I; Katafigiotis I; van der Poel H; Grivas N; Mitropoulos D
Curr Oncol; 2024 Feb; 31(3):1162-1169. PubMed ID: 38534919
[TBL] [Abstract] [Full Text] [Related]
2. Prevalence of germline brca1/2 pathogenic variants in Japanese patients treated with castration-resistant prostate cancer and efficacy of CRPC treatment in real-world clinical practice.
Maekawa S; Takata R; Sekiguchi K; Kagabu M; Toyoshima M; Tamada S; Takahashi K; Ikarashi D; Matsuura T; Kato R; Kato Y; Kanehira M; Sugimura J; Abe T; Baba T; Obara W
Jpn J Clin Oncol; 2024 Apr; 54(4):489-497. PubMed ID: 38157885
[TBL] [Abstract] [Full Text] [Related]
3. Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer.
Wan H; Zhan X; Li X; Chen T; Deng X; Liu Y; Deng J; Fu B; Li Y
BMC Urol; 2023 Nov; 23(1):182. PubMed ID: 37950252
[TBL] [Abstract] [Full Text] [Related]
4. BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype.
Fettke H; Dai C; Kwan EM; Zheng T; Du P; Ng N; Bukczynska P; Docanto M; Kostos L; Foroughi S; Brown S; Graham LK; Mahon K; Horvath LG; Jia S; Kohli M; Azad AA
EBioMedicine; 2023 Sep; 95():104738. PubMed ID: 37549632
[TBL] [Abstract] [Full Text] [Related]
5. Investigation of Clinically Significant Molecular Aberrations in Patients with prostate cancer: Implications for Personalized Treatment, prognosis and Genetic Testing.
Fountzilas E; Kouspou M; Eliades A; Papadopoulou K; Bournakis E; Goussia A; Tsiatas M; Achilleos A; Tsangaras K; Billioud G; Loizides C; Lemesios C; Kypri E; Ioannides M; Koumbaris G; Levva S; Vakalopoulos I; Paliouras A; Pervana S; Koinis F; Bumci R; Christopoulou A; Meditskou S; Psyrri A; Boukovinas I; Visvikis A; Karavasilis V; Koukoulis GK; Kotsakis A; Giannakis D; Fountzilas G; Patsalis PC
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511593
[TBL] [Abstract] [Full Text] [Related]
6. Somatic and Germline Variants Affect prognosis and Susceptibility in prostate cancer.
Rocca C; Rocca G; Zampieri P; Dell'atti L; Bianchi N; Ippolito C; Aguiari G
Anticancer Res; 2023 Jul; 43(7):2941-2949. PubMed ID: 37351993
[TBL] [Abstract] [Full Text] [Related]
7. Use of PARP inhibitors in prostate cancer: from specific to broader application.
Zhang Z; Diao L; Zhang C; Wang F; Guan X; Yao X
Front Endocrinol (Lausanne); 2023; 14():1164067. PubMed ID: 37152924
[TBL] [Abstract] [Full Text] [Related]
8. Estimating copy number to determine BRCA2 deletion status and to expect prognosis in localized prostate cancer.
Nukaya T; Sumitomo M; Sugihara E; Takeda M; Nohara S; Tanishima S; Takenaka M; Zennami K; Takahara K; Shiroki R; Saya H
Cancer Med; 2023 Apr; 12(7):8154-8165. PubMed ID: 36645189
[TBL] [Abstract] [Full Text] [Related]
9. The germline mutational landscape of genitourinary cancers and its indication for prognosis and risk.
Yang Y; Zhang G; Hu C; Luo W; Jiang H; Liu S; Yang H
BMC Urol; 2022 Nov; 22(1):196. PubMed ID: 36451132
[TBL] [Abstract] [Full Text] [Related]
10. The prevalence of gene mutations in homologous recombination repair pathways in Japanese patients with metastatic castration-resistant prostate cancer in real-world clinical practice: The multi-institutional observational ZENSHIN study.
Uemura H; Oya M; Kamoto T; Sugimoto M; Shinozaki K; Morita K; Koto R; Takahashi M; Nii M; Shin E; Nonomura N
Cancer Med; 2023 Mar; 12(5):5265-5274. PubMed ID: 36358026
[TBL] [Abstract] [Full Text] [Related]
11. Cell-Free DNA Variant Sequencing Using Plasma and AR-V7 Testing of Circulating Tumor Cells in prostate cancer Patients.
Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
Cells; 2021 Nov; 10(11):. PubMed ID: 34831445
[TBL] [Abstract] [Full Text] [Related]
12. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract] [Full Text] [Related]
13. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.
Jayaram A; Wingate A; Wetterskog D; Wheeler G; Sternberg CN; Jones R; Berruti A; Lefresne F; Lahaye M; Thomas S; Gormley M; Meacham F; Garg K; Lim LP; Merseburger AS; Tombal B; Ricci D; Attard G
Ann Oncol; 2021 Jun; 32(6):726-735. PubMed ID: 33794293
[TBL] [Abstract] [Full Text] [Related]
14. Treatment-emergent neuroendocrine prostate cancer with a germline
Pandya D; Shah M; Kaplan F; Martino C; Levy G; Kazanjian M; Batter S; Martignetti J; Frank RC
Cold Spring Harb Mol Case Stud; 2021 Feb; 7(1):. PubMed ID: 33608381
[TBL] [Abstract] [Full Text] [Related]
15. Management of a prostate cancer Patient With Inherited Germline brca1 and BRCA2 Mutations: A Case Report.
Hemal S; DeWitt-Foy M; Klein EA
Urology; 2021 Jul; 153():129-131. PubMed ID: 33556450
[TBL] [Abstract] [Full Text] [Related]
16. [Correlations between pancreatic carcinoma and previous neoplasms.].
Gavazzi F; Giordano L; Nebbia M; Luberto A; Izzo A; Zerbi A
Recenti Prog Med; 2021 Jan; 112(1):81-88. PubMed ID: 33512363
[TBL] [Abstract] [Full Text] [Related]
17. Age-related mutational signature negatively associated with immune activity and survival outcome in triple-negative breast cancer.
Chen H; Chong W; Yang X; Zhang Y; Sang S; Li X; Lu M
Oncoimmunology; 2020 Jun; 9(1):1788252. PubMed ID: 32923150
[TBL] [Abstract] [Full Text] [Related]
18. Tumor protein expression of the DNA repair gene brca1 and lethal prostate cancer.
Stopsack KH; Gerke T; Zareba P; Pettersson A; Chowdhury D; Ebot EM; Flavin R; Finn S; Kantoff PW; Stampfer MJ; Loda M; Fiorentino M; Mucci LA
Carcinogenesis; 2020 Jul; 41(7):904-908. PubMed ID: 32556091
[TBL] [Abstract] [Full Text] [Related]
19. 69-Year-Old Man With Castration-Resistant prostate cancer Progressing After Docetaxel and Androgen Receptor-Targeting Agent.
Gonzalez-Ochoa E; Verduzco-Aguirre H; Crawford ED; Bourlon MT
Oncology (Williston Park); 2020 Apr; 34(4):. PubMed ID: 32293692
[TBL] [Abstract] [Full Text] [Related]
20. brca1-associated protein 1 expression and prognostic role in prostate adenocarcinoma.
Oh H; Lee YJ; Kang SG; Ahn B; Kim E; Chae YS; Lee Y; Lee JH; Kim CH
Investig Clin Urol; 2020 Mar; 61(2):166-172. PubMed ID: 32158967
[TBL] [Abstract] [Full Text] [Related]
[Next]
